The design of the proposed clinical trial, Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients with Advanced Dry-Form Age-Related Macular Degeneration with Geographic Atrophy, is based on a pre-IND meeting with the FDA and a series of earlier interactions with the agency. Patients will undergo a single transplantation and the study will explore three different doses of OpRegen. Following transplantation, the patients will be followed over 12 months at specified intervals and then at longer time periods, to evaluate the safety and tolerability of the product. A secondary objective of the clinical trial will be to explore the ability of transplanted OpRegen to engraft, survive, and moderate the disease progression.
The filing of this IND is the culmination of 12 years of research and development starting at the Hadassah Human Embryonic Stem Cell Research Center at Hadassah University Medical Center, Jerusalem, Israel, under the direction of Prof. Benjamin Reubinoff, MD, PhD and continuing at Cell Cure Neurosciences Ltd., said Charles S. Irving Ph.D., Cell Cures CEO. We look forward to initiating the clinical trial that will, for the first time, utilize xeno-free grade human embryonic stem cell derived RPE cells with high purity and potency, for the treatment of geographic atrophy, the severe stage of dry-AMD.
About Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is one of the major diseases of aging and is the leading eye disease responsible for visual impairment of older persons in the US, Europe and Australia. AMD affects the macula, which is the part of the retina responsible for sharp, central vision that is important for facial recognition, reading and driving. There are two forms of AMD. The dry form (dry-AMD) advances slowly and painlessly until it progresses to the severe form called geographic atrophy (GA). Once the atrophy reaches the fovea (the center of the macula), patients lose their central vision and may develop legal blindness. There is currently no effective treatment for dry-AMD. There are about 1.6 million new cases of dry-AMD in the US annually. The yearly economic loss to the gross domestic product in the United States from dry-AMD has been estimated to be $24.4 billion. The market opportunity for a treatment for GA has been estimated at over $5 billion globally. About 10% of patients with dry-AMD develop wet-AMD, which is an acute disease and can lead to severe visual loss in a matter of weeks. Wet-AMD can be treated with currently-marketed VEGF inhibitors such as Lucentis or Eylea, however, such products typically require frequent repeated injections in the eye, and patients often continue to suffer from the continued progression of the underlying dry-AMD disease process. Current estimated annual sales of VEGF inhibitors for the treatment of the wet form of AMD are estimated to be about $7 billion worldwide. The root cause of the larger problem of dry-AMD is believed to be the dysfunction of RPE cells. One of the most exciting therapeutic approaches to dry-AMD is the transplantation of healthy, young RPE cells to support and replace the patients old degenerating RPE cells and to head off the advancing atrophy before it reaches the fovea. One of the most promising sources of healthy RPE cells is cells derived from pluripotent stem cells.
About OpRegen
Cell Cure's OpRegen consists of RPE cells that are produced using a proprietary process that drives the differentiation of human embryonic stem cells into high purity RPE cells. OpRegen is also xeno-free," meaning that no animal products were used either in the derivation and expansion of the human embryonic stem cells or in the directed differentiation process. The avoidance of the use of animal products eliminates some safety concerns. OpRegen is formulated as a suspension of RPE cells. Preclinical studies in mice have shown that following a single subretinal injection of OpRegen as a suspension of cells, the cells can rapidly organize into their natural monolayer structure and survive throughout the lifetime of the animal. OpRegen will be an off-the-shelf allogeneic product provided to retinal surgeons in a final formulation ready for transplantation. Unlike treatments that require multiple injections into the eye, such as currently-marketed products like Lucentis and Eylea for wet-AMD, it is expected that OpRegen would be administered in a single procedure.
About Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. was established in 2005 as a subsidiary of ES Cell International Pte. Ltd. (ESI), now a subsidiary of BioTime, Inc. (NYSE MKT: BTX). Cell Cures second largest shareholder is HBL Hadasit Bio-Holdings, (TASE: HDST, OTC: HADSY). Cell Cure is located in Jerusalem, Israel on the campus of Hadassah Medical Center. Cell Cure's mission is to become a leading supplier of human cell-based therapies for the treatment of retinal and neural degenerative diseases. Its technology platform is based on the manufacture of diverse cell products sourced from clinical-grade (GMP-compatible) human embryonic stem cells. Its current focus is the development of retinal pigment epithelial (RPE) cells for the treatment of age-related macular degeneration. Cell Cure's major shareholders include BioTime, Inc., HBL Hadasit Bio-Holdings Ltd., Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA), and Asterias Biotherapeutics (OTCBB: ASTY). Additional information about Cell Cure can be found on the web at http://www.cellcureneurosciences.com. A video of a presentation by Cell Cures CEO Dr. Charles Irving is available on BioTimes website.
About BioTime
BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTimes focus is on pluripotent stem cell technology based on human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTimes therapeutic and research products include a wide array of proprietary PureStem progenitors, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (a HyStem product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications, and is planning to initiate a pivotal clinical trial around Renevia, in 2014. In addition, BioTime has developed Hextend, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ HealthCare Corporation, under exclusive licensing agreements.
Originally posted here:
BioTimes Subsidiary Cell Cure Neurosciences Ltd. Files an IND with the FDA for OpRegen Designed to Treat Patients ...
- Stem Cells In Human Trials - September 15th, 2011 [September 15th, 2011]
- NZ Stemcell Trials - Part One - September 15th, 2011 [September 15th, 2011]
- CIRM Major Facilities Speed Stem Cell Science and Create Jobs - September 15th, 2011 [September 15th, 2011]
- Geron's Embryonic Stem Cell Clinical Trial for Spinal Cord Injury - September 15th, 2011 [September 15th, 2011]
- Hans Keirstead - Stem Cell Research Human Clinical Trials - September 15th, 2011 [September 15th, 2011]
- Stem-Cell Human Trials - September 15th, 2011 [September 15th, 2011]
- Geron: FDA Clearance for Human Clinical Stem Cell Trials - September 15th, 2011 [September 15th, 2011]
- Eric Legrand Rutgers University shout out, Listen up! - September 20th, 2011 [September 20th, 2011]
- How to Mend a Broken Heart - September 20th, 2011 [September 20th, 2011]
- Human Embryonic Stem Cell History! - September 20th, 2011 [September 20th, 2011]
- Robert Lanza - ACT - Stem cells and organ cloning interview - September 20th, 2011 [September 20th, 2011]
- Toonari Post Health News: Europe's first clinical trial using human embryonic stem cells - September 23rd, 2011 [September 23rd, 2011]
- Diabetes: Spotlight on Stem Cell Research - Ed Baetge - September 23rd, 2011 [September 23rd, 2011]
- Talking Apes being created by Science | Planet of the Apes, here we come! - September 24th, 2011 [September 24th, 2011]
- Health news: Internet use, sleep, human stem cell research - September 24th, 2011 [September 24th, 2011]
- Geron - September 24th, 2011 [September 24th, 2011]
- Batten Disease: Spotlight on Stem Cell Research - A Father's Story - September 24th, 2011 [September 24th, 2011]
- The Frankenstein Syndrome Trailer - September 24th, 2011 [September 24th, 2011]
- Leukemia: Spotlight on Stem Cell Research - Patient Stories - September 24th, 2011 [September 24th, 2011]
- Geron Corp. Initiates First Human Study Of Embryonic Stem-Cell Therapy - September 24th, 2011 [September 24th, 2011]
- Cardiovascular Therapies: Spotlight on Stem Cell Research - Yung-Wei Chi - September 24th, 2011 [September 24th, 2011]
- Stemcells come alive: Fix Mouse with severed spine ABCnews - September 24th, 2011 [September 24th, 2011]
- StemCells Gains 5% on Neural Stem Cell Trial in Spinal Cord Injury - September 24th, 2011 [September 24th, 2011]
- Stem-Cell Research on Animals - September 24th, 2011 [September 24th, 2011]
- First hESC Therapy Clinical Trial - September 24th, 2011 [September 24th, 2011]
- Stem Cell Testing on Human Subjects [Officially] Begins • NBC Nightly News • October 11th, 2010 - September 24th, 2011 [September 24th, 2011]
- Leukemia: Spotlight on Stem Cell Research - Catriona Jamieson - September 24th, 2011 [September 24th, 2011]
- First stem cell trial begins - September 24th, 2011 [September 24th, 2011]
- Parkinson's Disease: Spotlight on Stem Cell Research - Arnold Kriegstein - September 24th, 2011 [September 24th, 2011]
- Becoming a Blood Stem Cell Donor - September 24th, 2011 [September 24th, 2011]
- Stem cells might be able to reverse the effects of a heart attack. - September 24th, 2011 [September 24th, 2011]
- Horse Stem Cell Video.mp4 - September 25th, 2011 [September 25th, 2011]
- Stem cell trials to begin - September 25th, 2011 [September 25th, 2011]
- Lou Gehrig's Disease (ALS): Progress and Promise in Stem Cell Research - September 25th, 2011 [September 25th, 2011]
- Hans Keirstead - September 25th, 2011 [September 25th, 2011]
- Stem Cell Quiz - September 25th, 2011 [September 25th, 2011]
- NZ Stemcell Trials - Part Two - September 25th, 2011 [September 25th, 2011]
- Drug Trials in a Dish - September 25th, 2011 [September 25th, 2011]
- Rise and Walk - September 25th, 2011 [September 25th, 2011]
- Catriona Jamieson: Therapies Based on Cancer Stem Cells - September 27th, 2011 [September 27th, 2011]
- Vatican lending hand in adult stem cell research - September 28th, 2011 [September 28th, 2011]
- Why STEM-Enhance? - September 28th, 2011 [September 28th, 2011]
- Genetic Underpinnings of Alopecia Areata - September 29th, 2011 [September 29th, 2011]
- Batten Disease: Spotlight on Stem Cell Research - Ann Tsukamoto - September 29th, 2011 [September 29th, 2011]
- stem cell trial for leading causes of blindness - October 9th, 2011 [October 9th, 2011]
- Forbes Discusses Stem Cell Research - Video - October 13th, 2011 [October 13th, 2011]
- Bruce Conklin: Drug screening with stem cells - Video - October 13th, 2011 [October 13th, 2011]
- Human Trials of Embryonic Stem Cell Treatment Beginning - Video - October 13th, 2011 [October 13th, 2011]
- Rise and Walk - Video - October 13th, 2011 [October 13th, 2011]
- Mesenchymal Stem Cell Trials - Video - October 14th, 2011 [October 14th, 2011]
- Spinal Cord Injury: Progress and Promise in Stem Cell Research - Video - October 14th, 2011 [October 14th, 2011]
- Better Drugs Through Stem Cells - Video - October 16th, 2011 [October 16th, 2011]
- Adult Stem Cells Used To Rebuild Heart Tissue / Video - Video - October 16th, 2011 [October 16th, 2011]
- GARY RABIN- ADVANCED CELL TECHNOLOGIES 2011 - Video - October 21st, 2011 [October 21st, 2011]
- Stem cell treatment on horse a success, vet says - Video - October 21st, 2011 [October 21st, 2011]
- MAJOR EMBRYONIC STEM CELL BREAKTHROUGHS - Video - October 22nd, 2011 [October 22nd, 2011]
- Batten Disease: Spotlight on Stem Cell Research - Stephen Huhn - Video - November 13th, 2011 [November 13th, 2011]
- Human Cloning has Begun | Playing God? - Video - November 15th, 2011 [November 15th, 2011]
- Diabetes: Advancing Stem Cell Therapies - 2011 CIRM Grantee Meeting - Video - November 15th, 2011 [November 15th, 2011]
- Brain Tumors: Advancing Stem Cell Therapies - 2011 CIRM Grantee Meeting - Video - November 15th, 2011 [November 15th, 2011]
- Double Blind Trial of Stem Cells for Heart Failure - Video - December 4th, 2011 [December 4th, 2011]
- Cardiac Stem Cell Therapy Clinical Trial - Video - December 4th, 2011 [December 4th, 2011]
- Glasgow Hospital Conducts First Stem Cell Trials on Stroke Patients - Video - December 4th, 2011 [December 4th, 2011]
- Dr Dietrich discusses the Geron stem cell trial to treat acute spinal cord injury - Video - December 4th, 2011 [December 4th, 2011]
- Stem Cell Research Today: Larry Goldstein - CIRM Science Writer's Seminar - Video - December 7th, 2011 [December 7th, 2011]
- Stem Cell Clinical Trial for Heart Failure: Eduardo Marban - CIRM Spotlight on Disease - Video - December 22nd, 2011 [December 22nd, 2011]
- Clinical trials and stem cells: what patients should consider - Video - January 2nd, 2012 [January 2nd, 2012]
- Spare Parts for Humans: Tissue Engineers Aim for Lab-Grown Limbs, Lungs and More - Video - January 4th, 2012 [January 4th, 2012]
- CIRM Grant Writing: RFA's - Where does your Project Fit? - Video - January 5th, 2012 [January 5th, 2012]
- Prometheus and I: building new body parts from stem cells (15 Nov 2011) - Video - January 5th, 2012 [January 5th, 2012]
- News Bulletin 18 November 2011 -- The Christian Institute - Video - January 5th, 2012 [January 5th, 2012]
- The Brain on Trial: How Neuroscience Challenges the Law as We Know It - Video - January 5th, 2012 [January 5th, 2012]
- The Human Genome and Individualized Medicine - David Valle, MD - Video - January 5th, 2012 [January 5th, 2012]
- 2010 Professional of Distinction - Discovery Awards - Video - January 23rd, 2012 [January 23rd, 2012]
- Research at The Nebraska Medical Center Biologics Production Facility - Video - January 24th, 2012 [January 24th, 2012]
- ACT Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial Using hESC-Derived ... - January 30th, 2012 [January 30th, 2012]
- StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision - January 31st, 2012 [January 31st, 2012]
- $30 million donation from Boris family will help McMaster turn stem cell research into therapy - February 6th, 2012 [February 6th, 2012]
- Stem Cell Treatment For Blindness Shows Promise In Trials - February 7th, 2012 [February 7th, 2012]
- ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from ... - February 13th, 2012 [February 13th, 2012]